Patients initiated on long-acting injectables for the treatment of schizophrenia had fewer hospitalizations and emergency department visits, compared with patients treated with oral antipsychotics, according to a poster presented at Psych Congress…
The metabolic profile of lumateperone 42 mg appears favorable, according to a post hoc analysis of a trio of studies involving patients with schizophrenia. Researchers shared their findings at Psych Congress 2020.
In patients with recent-onset schizophrenia, the rate of major treatment failure with longer treatment was lower with paliperidone palmitate than with oral antipsychotics, according to a poster presented at Psych Congress 2020.
In this podcast, Jonathan Meyer, MD, discusses the role of D2 antagonism in schizophrenia treatment, lessons learned about schizophrenia treatment from clozapine, and emerging treatments for schizophrenia and their therapeutic targets.
A large-scale analysis of insurance databases found a high prevalence of medical and psychiatric comorbidities among patients with schizophrenia, compared with matched controls, according to a poster presented at Psych Congress 2020.
HP-3070, the asenapine transdermal system, has a more predictable absorption profile and lower peak-to-trough fluctuations than sublingual asenapine, according to a poster presented at Psych Congress 2020.
Sustained use of the antipsychotic olanzapine in patients with remitted psychotic depression was associated with a thinning of the cortex, when compared with placebo, according to a study published online in JAMA Psychiatry.